Introduction: Individualized homeopathy (IH) in atopic dermatitis (AD) remained under-researched. Objective: We aimed at evaluating efficacy of IH in AD. Methods: A double-blind, randomized, placebo-controlled, short-term, preliminary trial was conducted in an Indian homeopathy hospital. Patients were randomized to either IH (n = 30) or identical-looking placebo (n = 30) using computerized randomization and allocation. Outcomes were patient-oriented scoring of AD (PO-SCORAD; primary end point), Dermatological Life Quality Index (DLQI) score, and AD burden score for adults (ADBSA; secondary end points), measured monthly for 3 months. An intention-to-treat sample was analyzed after adjusting baseline differences. Results: On PO-SCORAD, improvement was higher in IH against placebo, but nonsignificant statistically (p_{month 1} = 0.433, p_{month 2} = 0.442, p_{month 3} = 0.229). Secondary outcomes were also nonsignificant – both DLQI and ADBSA (p #x3e; 0.05). Four adverse events (diarrhea, injury, common cold) were recorded. Conclusions: There was a small, but nonsignificant direction of effect towards homeopathy, which renders the trial inconclusive. A properly powered robust trial is indicated.
Complement Med Res

中文翻译：

---

个体化顺势疗法药物治疗成人特应性皮炎的疗效：一项双盲、随机、安慰剂对照的初步试验

简介：特应性皮炎 (AD) 中的个体化顺势疗法 (IH) 仍未得到充分研究。目的：我们旨在评估 IH 在 AD 中的疗效。方法：在印度顺势疗法医院进行了一项双盲、随机、安慰剂对照、短期初步试验。使用计算机化随机化和分配将患者随机分配至 IH ( n = 30) 或外观相同的安慰剂 ( n = 30)。结果是针对患者的 AD 评分（PO-SCORAD；主要终点）、皮肤病生活质量指数（DLQI）评分和成人 AD 负担评分（ADBSA；次要终点），每月测量 3 个月。在调整基线差异后分析意向治疗样本。结果：在 PO-SCORAD 上，与安慰剂相比，IH 的改善更高，但在统计学上不显着（第_{1 个月}= 0.433，第_{2 个月}= 0.442，第_{3 个月}= 0.229）。次要结局也不显着——DLQI 和 ADBSA（ p #x3e；0.05）。记录了四种不良事件（腹泻、受伤、普通感冒）。结论：顺势疗法的作用方向很小，但不显着，这使得试验没有结论。指示了适当供电的稳健试验。
补充医学资源